Russia propels Podravka’s growth
This article was originally published in OTC Bulletin & The Rose Sheet
Executive Summary
Higher demand in Russia and expanded distribution in Central European markets pushed up Podravka’s Pharmaceuticals sales by 6.4% to HrK433 million (€58.2 million) in the first half of this year. On a constant-currency basis, the Croatian company said the growth was 10.1%.